EWP
ALNY icon

Elevation Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Elevation Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6
Closed -$2.39K – 1080
2025
Q4 		$2.39K Buy
+6
New +$2.65K ﹤0.01% 765

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Elevation Wealth Partners's ALNY Position: Q1 2026 in Review

Elevation Wealth Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 6 shares — an estimated $2.39K sold.

Elevation Wealth Partners first reported a position in ALNY in Q4 2025 and held it in 1 quarter. The position peaked at $2.39K in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Elevation Wealth Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Elevation Wealth Partners sold 6 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $2.39K.
  • Elevation Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Elevation Wealth Partners's Alnylam Pharmaceuticals position peaked at $2.39K in Q4 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Elevation Wealth Partners's 13F filing for Q1 2026, filed 14 Apr 2026.